Skip to content
OpenCapital
Get started

Larimar Therapeutics LRMR Q4 2025 Annual earnings

Reported March 19, 2026 · Before market open

Diluted EPS-$0.73Miss by $0.29
EPS estimate-$0.44

Next report

Aug 13, 2026 (in a month)
EPS estimate-$0.39

Versus estimates

Revenue

Q4 2024$241.0K

Diluted EPS

Q1 2026-$0.31Beat by $0.22
Q4 2025-$0.73Miss by $0.29
Q3 2025-$0.61Miss by $0.22Q2 2025-$0.41Beat by $0.06Q1 2025-$0.46Miss by $0.04Q4 2024-$0.45Miss by $0.16

Ask the moment Larimar Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Larimar Therapeutics report Q4 2025 earnings?
Larimar Therapeutics (LRMR) reported Q4 2025 earnings on March 19, 2026 before market open.
What were Larimar Therapeutics's Q4 2025 revenue and EPS?
Larimar Therapeutics reported diluted EPS of $-0.73 for Q4 2025.
Did Larimar Therapeutics beat estimates in Q4 2025?
EPS missed the consensus estimate of $-0.44 by $0.29.
How did Larimar Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 62.2% from $-0.45.
Where can I find Larimar Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-115119) and the 10-K periodic report (0001193125-26-115878) directly on SEC EDGAR. The filing index links above go to sec.gov.